Results 61 to 70 of about 23,635 (276)

Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome [PDF]

, 2018
Stevens-Johnson syndrome is a rare adverse cutaneous drug reaction characterized by epidermal detachment of
Al-Omari, Ahmed, Rancour, Elizabeth A., Shah, Kishan M.   +2 more
core  

Buccal Mucosa as Substrate for Direct Immunofluorescence Should Be Included Early in the Diagnostic Work Up of Ocular Mucous Membrane Pemphigoid

JEADV Clinical Practice, EarlyView.
ABSTRACT Background In ocular mucous membrane pemphigoid (MMP) direct immunofluorescence (DIF) represents the gold standard for definitive diagnosis. However, up to 50% of ocular MMP cases do not meet the immunopathological criteria. In addition, the risk of exacerbating conjunctival cicatrization makes ocular biopsy technically difficult to obtain ...
Andrea Gabusi, Michelangelo La Placa, Davide Bartolomeo Gissi, Federica Filippi, Camilla Loi, Cosimo Misciali, Federico Bardazzi   +6 more
wiley   +1 more source

Systemic Implications of Bullous Pemphigoid: Bridging Dermatology and Internal Medicine

Diagnostics
Background: Bullous pemphigoid is an autoimmune bullous disease that frequently affects a large skin surface area, but it can also present in localized areas.
Emi Mashima, Natsuko Saito-Sasaki, Yu Sawada   +2 more
doaj   +1 more source

Pemphigoid vegetans in childhood: A case report and short review of literature

Indian Journal of Dermatology, 2015
Pemphigoid vegetans is a very rare type of bullous pemphigoid which usually affects the elderly and has not been reported in children. It shows a clinical resemblance to pemphigus vegetans but has distinct histological and immunopathological features of ...
Yasmeen Khatib, Meena Makhija, Richa D Patel, Gayatri Karad   +3 more
doaj   +1 more source

Metronidazole-Induced Bullous Pemphigoid: A Case Report [PDF]

Journal of Clinical and Diagnostic Research, 2015
Bullous pemphigoid is an autoimmune cutaneous blistering disorder, the exact pathogenesis of which is still not fully elucidated. Drug-induced bullous pemphigoid eruptions are rare but have been reported earlier with the use of frusemide, psoralens ...
Saibal Moitra, Sukanta Sen, Indranil Banerjee, Ayan Sikder, Prasanta Das   +4 more
doaj   +1 more source

Granulomatous Panniculitis in a Patient Treated With Cemiplimab: Case Report and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced malignancies by enhancing antitumor immunity, but they may also trigger a broad spectrum of immune‐related adverse events (irAEs) involving multiple organs.
B. Lada‐Colunga, J. L. Artola‐Igarza, N. Martinez‐Peña, I. Arevalo‐Ortega, J. Rodriguez‐Blandon, G. Cancho‐Galan, R. Izu‐Belloso   +6 more
wiley   +1 more source

Rituximab for Acquired Hemophilia A in the Setting of Bullous Pemphigoid [PDF]

, 2022
Maria C Bell
openalex   +1 more source

Successful Treatment of Severe Adult Linear IgA Dermatosis Using Dupilumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Linear IgA dermatosis (LAD) is a rare autoimmune subepidermal bullous dermatosis, characterised by the presence of erythematous vesiculobullous lesions arranged in rosettes or herpetiform clusters. The standard treatment involves the administration of dapsone, followed by sulfasalazine, and general corticosteroid therapy, often in combination ...
Célia Delesalle, Claire Abasq‐Thomas, Claire Bocciarelli, Amélie Bourhis, Marina Alexandre, Belen Eguia, Laurent Misery, Numa Deydier   +7 more
wiley   +1 more source

Direct and indirect immunofluorescence [PDF]

, 2010
A imunofluorescência é um valioso instrumento auxiliar no diagnóstico das dermatoses bolhosas autoimunes e desordens inflamatórias, uma vez que seus achados clínicos e histopatológicos podem não ser determinantes.
AOKI, Valéria, FREITAS, Elder L., FUKUMORI, Lígia M. I., OLIVEIRA, Zilda N. P., PÉRIGO, Alexandre M., SOUSA JR, Joaquim X.   +5 more
core   +2 more sources

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki, Ryo Saito, Kenta Suzuki, Daisuke Watanabe, Masako Minami‐Hori, Hirofumi Kamada, Hiroo Amano, Akihiko Uchiyama, Sei‐ichiro Motegi, Machiko Kamura, Kazunari Sugita, Noriko Kubota, Toshifumi Nomura, Maki Ozawa, Toshiya Takahashi, Takashi Yamakita, Kazumitsu Sugiura, Tetsuharu Ikegami, Ken Igawa, Yuka Kimura, Yoko Kataoka, Ryoichi Kamide, Masakazu Takahashi, Akio Tanaka, Mariko Sugawara‐Mikami   +24 more
wiley   +1 more source